Salvador, R.; Moutinho, C.G.; Sousa, C.; Vinha, A.F.; Carvalho, M.; Matos, C.
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals 2025, 18, 399.
https://doi.org/10.3390/ph18030399
AMA Style
Salvador R, Moutinho CG, Sousa C, Vinha AF, Carvalho M, Matos C.
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals. 2025; 18(3):399.
https://doi.org/10.3390/ph18030399
Chicago/Turabian Style
Salvador, Rui, Carla Guimarães Moutinho, Carla Sousa, Ana Ferreira Vinha, Márcia Carvalho, and Carla Matos.
2025. "Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment" Pharmaceuticals 18, no. 3: 399.
https://doi.org/10.3390/ph18030399
APA Style
Salvador, R., Moutinho, C. G., Sousa, C., Vinha, A. F., Carvalho, M., & Matos, C.
(2025). Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals, 18(3), 399.
https://doi.org/10.3390/ph18030399